We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Dyadic Welcomes New Chief Operating Officer

News   May 10, 2013

 
Dyadic Welcomes New Chief Operating Officer
 
 
 

RELATED ARTICLES

Rockland Immunochemicals, Inc. CSO Opines “Benefits of Polyclonal Antibodies” in Peer-reviewed Article

News

Dr. Carl Ascoli, Chief Science Officer at Rockland, and Dr. Birte Aggeler, Director of Antibody Development at Bio-Techne, have composed a review article on the pros and cons of polyclonal, conventional monoclonal, and recombinant monoclonal antibodies.

READ MORE

A Powerful Approach for Stopping Ebola Outbreaks

News

A one-two punch of powerful antibodies may be the best way to stop Ebola virus. Recent findings suggest new therapies should disable Ebola virus’s infection machinery and spark the patient’s immune system to call in reinforcements.

READ MORE

Novel Drug Could Potentially Treat Liver Cancer More Effectively

News

A research team has developed a novel peptide drug called FFW that could potentially stop the development of hepatocellular carcinoma (HCC) or primary liver cancer.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE